- Home
- STTK vs ESLA Comparison
STTK vs ESLA Comparison
Compare STTK & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- ESLA
- Stock Information
- Founded
- STTK 2016
- ESLA 2021
- Country
- STTK United States
- ESLA United States
- Employees
- STTK N/A
- ESLA N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- ESLA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STTK Health Care
- ESLA Health Care
- Exchange
- STTK Nasdaq
- ESLA Nasdaq
- Market Cap
- STTK 37.6M
- ESLA 35.5M
- IPO Year
- STTK 2020
- ESLA N/A
- Fundamental
- Price
- STTK $1.14
- ESLA $1.07
- Analyst Decision
- STTK Hold
- ESLA Strong Buy
- Analyst Count
- STTK 4
- ESLA 1
- Target Price
- STTK $3.00
- ESLA $16.00
- AVG Volume (30 Days)
- STTK 101.1K
- ESLA 518.6K
- Earning Date
- STTK 07-31-2025
- ESLA 06-17-2025
- Dividend Yield
- STTK N/A
- ESLA N/A
- EPS Growth
- STTK N/A
- ESLA N/A
- EPS
- STTK N/A
- ESLA N/A
- Revenue
- STTK $4,606,000.00
- ESLA N/A
- Revenue This Year
- STTK N/A
- ESLA $101.09
- Revenue Next Year
- STTK N/A
- ESLA N/A
- P/E Ratio
- STTK N/A
- ESLA N/A
- Revenue Growth
- STTK 69.65
- ESLA N/A
- 52 Week Low
- STTK $0.69
- ESLA $0.63
- 52 Week High
- STTK $7.49
- ESLA $3.23
- Technical
- Relative Strength Index (RSI)
- STTK 56.02
- ESLA 55.18
- Support Level
- STTK $0.98
- ESLA $0.78
- Resistance Level
- STTK $1.13
- ESLA $1.18
- Average True Range (ATR)
- STTK 0.10
- ESLA 0.10
- MACD
- STTK 0.01
- ESLA 0.00
- Stochastic Oscillator
- STTK 84.85
- ESLA 71.28
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.